Meth bill vote pledged
This article was originally published in The Tan Sheet
Senate leadership has agreed to vote in January or early February on legislation that would put OTC cough/cold products containing pseudoephedrine behind the counter, according to Combat Meth Act cosponsor Sen. Dianne Feinstein (D-Calif.). A version of the bill was attached to the Patriot Act reauthorization conference report but was left behind when the Senate reached a compromise Dec. 22 to extend Patriot by five weeks without the report. Feinstein is considering seeking another vehicle or attempting to pass the meth Act as a stand-alone bill; however, according to her office, the bill likely will resurface as an amendment to the Patriot Act, which will require reauthorization prior to Feb. 3...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.